首页|丁苯酞-哒嗪酮衍生物的设计、合成及其抗凝活性研究

丁苯酞-哒嗪酮衍生物的设计、合成及其抗凝活性研究

扫码查看
为了提高丁苯酞的抗血小板凝集活性,以6-氨基丁苯酞为起始原料,经重氮化/还原、环化、水解、脱氯、醚化和磺酰化反应合成了 20个新型的丁苯酞-哒嗪酮衍生物,其结构经1H NMR、13C NMR和HRMS确证.体外抗血小板凝集活性测试结果表明,化合物6a、6b和6k对二磷酸腺苷(ADP)诱导的血小板凝集的抑制活性(IC50=44.9~180.0μmol/L)优于先导化合物丁苯酞(IC50=1252μmol/L)和阳性对照阿司匹林(IC50=1140μmol/L);同时,化合物 6b(IC50=63.6μmol/L)和 6k(IC50=191.9μmol/L)对花生四烯酸(AA)诱导的血小板凝集也表现出显著的抑制活性.本研究为丁苯酞-哒嗪酮骨架在治疗缺血性脑卒中方面的研究提供了理论参考.
Design,Synthesis and Anticoagulant Activity of Butylphthalide-Pyridazinone Derivatives
In order to improve the antiplatelet agglutination activity of butylphthalide,6-aminobutylphthalide was used as the starting material,twenty novel butylphthalide-pyridazinone derivatives were synthesized by diazotization/reduction,cyclization,hydrolysis,dechlorination,etherification and sulfonation acylation.Their structures were confirmed by 1H NMR,13C NMR and HRMS.The results of antiplatelet agglutination activity test in vitro show that compounds 6a,6b and 6k exhibite better inhibitory activity(IC50=44.9~180.0 μmol/L)against ADP-induced platelet aggregation than the lead compound butylphthalide(IC50=1252μmol/L)and positive control aspirin(IC50=1140 μmol/L).Meanwhile,compound 6b(IC50=63.6 μmol/L)and 6k(IC50=191.9 μmol/L)also possess significant inhibitory activity against AA-induced platelet aggregation.This study provides a theoretical reference for the study of butylphthalide-pyridazinone skeleton in the treatment of ischemic stroke.

Butylphthalide derivativePyridazinoneDesignSynthesisAnti-platelet aggregation activity

贾镇、张关丽、李毅、李永、汤磊、樊玲玲

展开 >

贵州医科大学药学院 贵州省化学合成药物研发利用工程技术研究中心 贵阳 550025

丁苯酞衍生物 哒嗪酮 设计 合成 血小板凝集活性

国家自然科学基金贵州省科技计划贵州省普通高等学校青年科技人才成长计划贵州省大学生创新创业训练计划(2021)

32060627黔科合基础-ZK[2023]一般309黔教合KY字[2022]246号S202110660026

2024

化学通报(印刷版)
中国科学院化学研究所 中国化学会

化学通报(印刷版)

CSTPCD北大核心
影响因子:0.547
ISSN:0441-3776
年,卷(期):2024.87(1)
  • 8